Armin Bauer
Otto-von-Guericke University Magdeburg
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Armin Bauer.
Angewandte Chemie | 2009
Hans Matter; Marc Nazare; Stefan Güssregen; David William Will; Herman Schreuder; Armin Bauer; Matthias Urmann; Kurt Ritter; Michael Wagner; Volkmar Wehner
Attractive chlorine: Noncovalent interactions between chlorine or bromine atoms and aromatic rings in proteins open up a new method for the manipulation of molecular recognition. Substitution at distinct positions of two factor Xa inhibitors improves the free energy of binding by interaction with a tyrosine unit. The generality of this motif was underscored by multiple crystal structures as well as high-level quantum chemical calculations (see picture).
Chemistry: A European Journal | 1999
Dieter Schinzer; Armin Bauer; Oliver M. Böhm; Anja Limberg; Martin Cordes
The sixteen-membered ring macrolide (–)-epothilone B 1 has been synthesized by a route which features stereospecific methylation of an (E)-γ,δ-epoxy acrylate, the use of a double asymmetric reaction employing (R,R)-diisopropyltartrate and (E)-crotylboronate, and ring closure by means of an olefin metathesis reaction.
Science | 2015
Angela Kling; Peer Lukat; Deepak Almeida; Armin Bauer; Evelyne Fontaine; Sylvie Sordello; Nestor Zaburannyi; Jennifer Herrmann; Silke C. Wenzel; Claudia König; Nicole C. Ammerman; María Belén Barrio; Kai Borchers; Florence Bordon-Pallier; Mark Brönstrup; Gilles Courtemanche; Martin Gerlitz; Michel Geslin; Peter Dr. Hammann; Dirk W. Heinz; Holger Hoffmann; Sylvie Klieber; Markus Kohlmann; Michael Kurz; Christine Lair; Hans Matter; Eric L. Nuermberger; Sandeep Tyagi; Laurent Fraisse; Jacques Grosset
New for old—TB drug development Tuberculosis (TB) is a global health threat for which there is only lengthy drug treatment. Patients need to consume multiple tablets over several months and frequently fail to complete their treatment. Consequently, drug-resistant strains of the pathogen have emerged, which add to the threat. Kling et al. revisited a natural product called griselimycin, extracted from the same organism that produced the prototype anti-TB drug, streptomycin. Unmodified griselimycin has poor pharmacological properties. However, one synthetic derivative had improved oral uptake and penetrated cells of the immune system that harbor the TB mycobacterium. In combination with other drugs, the griselimycin derivative showed high potency in mice with TB. Science, this issue p. 1106 A griselimycin-derived drug that blocks the DNA polymerase sliding clamp is a potent anti-tuberculosis lead. The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy. Despite the subsequent development of a curative regimen for this disease, tuberculosis remains a worldwide problem, and the emergence of multidrug-resistant Mycobacterium tuberculosis has prioritized the need for new drugs. Here we show that new optimized derivatives from Streptomyces-derived griselimycin are highly active against M. tuberculosis, both in vitro and in vivo, by inhibiting the DNA polymerase sliding clamp DnaN. We discovered that resistance to griselimycins, occurring at very low frequency, is associated with amplification of a chromosomal segment containing dnaN, as well as the ori site. Our results demonstrate that griselimycins have high translational potential for tuberculosis treatment, validate DnaN as an antimicrobial target, and capture the process of antibiotic pressure-induced gene amplification.
Angewandte Chemie | 2012
Marc Nazare; Hans Matter; David William Will; Michael Wagner; Matthias Urmann; Jörg Czech; Herman Schreuder; Armin Bauer; Kurt Ritter; Volkmar Wehner
Predictable thermodynamic additivity is one of the cornerstones of classical covalent chemistry, allowing accurate calculation of energy terms for complete processes by addition of terms for individual components. However this principle breaks down in complex noncovalent systems, such as biological systems, in which the energetics of individual components are not truly independent of each other. This complicates predicting protein structure and folding and, the focus of this work, the prediction of ligand binding to proteins. Molecular recognition in protein–ligand complexes predominantly occurs through multiple noncovalent interactions, whereas their contribution to the total free-energy of binding (DG) is often unevenly distributed over the contact interface. The identification of ligands as “molecular anchors” for high affinity regions in proteins (“hot spots”) is fundamental for fragment-based drug discovery, 3] indicating the similarity of ligandand protein-centric concepts. Often highaffinity ligands encompass more than one fragment in proximal protein sites; in a few cases, individual fragments in two neighboring sites could be linked to result in high binding affinity. Ideally, the DG of linked fragments should be significantly greater than the sum of DG increments from each fragment. This overproportional increase (“superadditivity”) is attributed to the fact that each fragment loses a significant part of its rigid body rotational and translational entropy upon complex formation. Thus, the sum of DG for two fragments includes two unfavorable rigid body entropy barrier terms, whereas the joined molecule is only affected by one of these terms. Any ligand has to overcome this barrier because of entropy loss upon association to its site. The nonadditivity for DG contributions is defined as linker coefficient E corresponding to the difference between the sums of fragment affinity and the final ligand [Eq. (1)]. DGfinal 1⁄4 DGfrag1 þ DGfrag2 þ DGlink with DGlink 1⁄4 R T ln E ð1Þ
Angewandte Chemie | 2015
Holger Hoffmann; Herbert Kogler; Winfried Heyse; Hans Matter; Michael Caspers; Dietmar Schummer; Christine Klemke-Jahn; Armin Bauer; Geraldine Penarier; Laurent Debussche; Mark Brönstrup
Microbial natural products are a rich source of bioactive molecules to serve as drug leads and/or biological tools. We investigated a little-explored myxobacterial genus, Nannocystis sp., and discovered a novel 21-membered macrocyclic scaffold that is composed of a tripeptide and a polyketide part with an epoxyamide moiety. The relative and absolute configurations of the nine stereocenters was determined by NMR spectroscopy, molecular dynamics calculations, chemical degradation, and X-ray crystallography. The compound, named nannocystin A (1), was found to inhibit cell proliferation at low nanomolar concentrations through the early induction of apoptosis. The mode of action of 1 could not be matched to that of standard drugs by transcriptional profiling and biochemical experiments. An initial investigation of the structure-activity relationship based on seven analogues demonstrated the importance of the epoxide moiety for high activity.
Chemistry: A European Journal | 2012
Cosima Dufour; Joachim Wink; Michael Kurz; Herbert Kogler; Helene Olivan; Serge Sablé; Winfried Heyse; Martin Gerlitz; Luigi Toti; Antje Nußer; Astrid Rey; Cédric Couturier; Armin Bauer; Mark Brönstrup
In an antibiotic lead discovery program, the known strain Streptomyces armeniacus DSM19369 has been found to produce three new natural products when cultivated on a malt-containing medium. The challenging structural elucidation of the isolated compounds was achieved by using three independent methods, that is, chemical degradation followed by NMR spectroscopy, a computer-assisted structure prediction algorithm, and X-ray crystallography. The compounds, named armeniaspirol A-C (2-4), exhibit a compact, hitherto unprecedented chlorinated spiro[4.4]non-8-ene scaffold. Labeling experiments with [1-(13)C] acetate, [1,2-(13)C2] acetate, and [U-(13)C] proline suggest a biosynthesis through a rare two-chain mechanism. Armeniaspirols displayed moderate to high in vitro activities against gram-positive pathogens such as methicillin-resistant S. aureus (MRSA) or vancomycin resistant E. faecium (VRE). As analogue 2 was active in vivo in an MRSA sepsis model, and showed no development of resistance in a serial passaging experiment, it represents a new antibiotic lead structure.
Journal of the American Chemical Society | 2015
Chengzhang Fu; Lena Keller; Armin Bauer; Mark Brönstrup; Alexandre Froidbise; Peter Dr. Hammann; Jennifer Herrmann; Guillaume Mondésert; Michael Kurz; Matthias Schiell; Dietmar Schummer; Luigi Toti; Joachim Wink; Rolf Müller
Telomycin (TEM) is a cyclic depsipeptide antibiotic active against Gram-positive bacteria. In this study, five new natural telomycin analogues produced by Streptomyces canus ATCC 12646 were identified. To understand the biosynthetic machinery of telomycin and to generate more analogues by pathway engineering, the TEM biosynthesis gene cluster has been characterized from S. canus ATCC 12646: it spans approximately 80.5 kb and consists of 34 genes encoding fatty acid ligase, nonribosomal peptide synthetases (NRPSs), regulators, transporters, and tailoring enzymes. The gene cluster was heterologously expressed in Streptomyces albus J1074 setting the stage for convenient biosynthetic engineering, mutasynthesis, and production optimization. Moreover, in-frame deletions of one hydroxylase and two P450 monooxygenase genes resulted in the production of novel telomycin derivatives, revealing these genes to be responsible for the specific modification by hydroxylation of three amino acids found in the TEM backbone. Surprisingly, natural lipopeptide telomycin precursors were identified when characterizing an unusual precursor deacylation mechanism during telomycin maturation. By in vivo gene inactivation and in vitro biochemical characterization of the recombinant enzyme Tem25, the maturation process was shown to involve the cleavage of previously unknown telomycin precursor-lipopeptides, to yield 6-methylheptanoic acid and telomycins. These lipopeptides were isolated from an inactivation mutant of tem25 encoding a (de)acylase, structurally elucidated, and then shown to be deacylated by recombinant Tem25. The TEM precursor and several semisynthetic lipopeptide TEM derivatives showed rapid bactericidal killing and were active against several multidrug-resistant (MDR) Gram-positive pathogens, opening the path to future chemical optimization of telomycin for pharmaceutical application.
Bioorganic & Medicinal Chemistry Letters | 2012
Cédric Couturier; Armin Bauer; Astrid Rey; Cosima Schroif-Dufour; Mark Broenstrup
Armeniaspiroles, a novel class of natural products isolated from Streptomyces armeniacus, are characterized by a novel spiro[4.4]non-8-ene scaffold. Various derivatives of Armeniaspiroles could be obtained by halogenation, alkylation, addition/elimination or reductions. A total synthesis of the 5-chloro analog of Armeniaspirole A has been accomplished in a linear six-step sequence. 5-Chloro-Armeniaspirole A exhibits good activity against a range of multidrug-resistant, Gram-positive bacterial pathogens.
Scientific Reports | 2016
Herman Schreuder; Alexander Liesum; Petra Lönze; Heike Di. Stump; Holger Hoffmann; Matthias Schiell; Michael Kurz; Luigi Toti; Armin Bauer; Christopher Kallus; Christine Klemke-Jahn; Jörg Czech; Dan Kramer; Heike Enke; Timo H. J. Niedermeyer; Vincent Morrison; Vasant Kumar; Mark Brönstrup
Mature thrombin activatable fibrinolysis inhibitor (TAFIa) is a carboxypeptidase that stabilizes fibrin clots by removing C-terminal arginines and lysines from partially degraded fibrin. Inhibition of TAFIa stimulates the degradation of fibrin clots and may help to prevent thrombosis. Applying a lead finding approach based on literature-mining, we discovered that anabaenopeptins, cyclic peptides produced by cyanobacteria, were potent inhibitors of TAFIa with IC50 values as low as 1.5 nM. We describe the isolation and structure elucidation of 20 anabaenopeptins, including 13 novel congeners, as well as their pronounced structure-activity relationships (SAR) with respect to inhibition of TAFIa. Crystal structures of the anabaenopeptins B, C and F bound to the surrogate protease carboxypeptidase B revealed the binding modes of these large (~850 Da) compounds in detail and explained the observed SAR, i.e. the strong dependence of the potency on a basic (Arg, Lys) exocyclic residue that addressed the S1’ binding pocket, and a broad tolerance towards substitutions in the pentacyclic ring that acted as a plug of the active site.
Bioorganic & Medicinal Chemistry Letters | 2015
Cédric Couturier; Sandra Silve; Renaud Morales; Bernard Pessegue; Sylvie Llopart; Anil Nair; Armin Bauer; Bodo Scheiper; Christoph Pöverlein; Axel Ganzhorn; Sophie Lagrange; Eric Bacqué
A series of imidazo[1,2-a]indeno[1,2-e]pyrazin-4-ones that potently inhibit M. tuberculosis glutamine synthetase (GlnA1) has been identified by high throughput screening. Exploration of this series was performed owing to a short chemistry program. Despite possibly nanomolar inhibitions, none of these compounds was active on whole cell Mtb, suggesting that GlnA1 may not be a suitable target to find new anti-tubercular drugs.